Search Results - "Rumde, Purva"

A Path to Persistence after EGFR Inhibition by Rumde, Purva H, Burns, Timothy F

“…Residual cancer cells persist even after targeted therapies, serving as a reservoir for the subsequent acquisition of genetic alterations that lead to acquired…”
Get full text

A Code of Mono-phosphorylation Modulates the Function of RB by Sanidas, Ioannis, Morris, Robert, Fella, Katerina A., Rumde, Purva H., Boukhali, Myriam, Tai, Eric C., Ting, David T., Lawrence, Michael S., Haas, Wilhelm, Dyson, Nicholas J.

“…Hyper-phosphorylation of RB controls its interaction with E2F and inhibits its tumor suppressor properties. However, during G1 active RB can be…”
Get full text

Chromatin-bound RB targets promoters, enhancers, and CTCF-bound loci and is redistributed by cell-cycle progression by Sanidas, Ioannis, Lee, Hanjun, Rumde, Purva H., Boulay, Gaylor, Morris, Robert, Golczer, Gabriel, Stanzione, Marcello, Hajizadeh, Soroush, Zhong, Jun, Ryan, Meagan B., Corcoran, Ryan B., Drapkin, Benjamin J., Rivera, Miguel N., Dyson, Nicholas J., Lawrence, Michael S.

“…The interaction of RB with chromatin is key to understanding its molecular functions. Here, for first time, we identify the full spectrum of chromatin-bound…”
Get full text

TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer by Kumar, Vinod, Yochum, Zachary A., Devadassan, Princey, Huang, Eric H.-B., Miller, Ethan, Baruwal, Roja, Rumde, Purva H., GaitherDavis, Autumn L., Stabile, Laura P., Burns, Timothy F.

“…MET amplification/mutations are important targetable oncogenic drivers in NSCLC, however, acquired resistance is inevitable and the majority of patients with…”
Get full text

Active RB causes visible changes in nuclear organization by Krishnan, Badri, Yasuhara, Takaaki, Rumde, Purva, Stanzione, Marcello, Lu, Chenyue, Lee, Hanjun, Lawrence, Michael S, Zou, Lee, Nieman, Linda T, Sanidas, Ioannis, Dyson, Nicholas J

“…RB restricts G1/S progression by inhibiting E2F. Here, we show that sustained expression of active RB, and prolonged G1 arrest, causes visible changes in…”
Get full text

Membrane-bound Gaussia luciferase as a tool to track shedding of membrane proteins from the surface of extracellular vesicles by Zaborowski, Mikołaj Piotr, Cheah, Pike See, Zhang, Xuan, Bushko, Isabella, Lee, Kyungheon, Sammarco, Alessandro, Zappulli, Valentina, Maas, Sybren Lein Nikola, Allen, Ryan M., Rumde, Purva, György, Bence, Aufiero, Massimo, Schweiger, Markus W., Lai, Charles Pin- Kuang, Weissleder, Ralph, Lee, Hakho, Vickers, Kasey C., Tannous, Bakhos A., Breakefield, Xandra O.

“…Extracellular vesicles (EVs) released by cells play a role in intercellular communication. Reporter and targeting proteins can be modified and exposed on the…”
Get full text

Treatment package time < 14 weeks improves recurrence free and disease specific survival in HPV positive OPC with high-risk features by Melachuri, Manasa, Kurukulasuriya, Chareeni, Rumde, Purva, Patel, Terral, Awad, Daniel, Kim, Seungwon, Ferris, Robert, Sridharan, Shaum, Duvvuri, Umamaheswar

“…•HPV + OPC with high-risk features is more sensitive to treatment delays.•Starting radiation < 6 weeks after TORS prolongs time to recurrence by…”
Get full text

Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit by Mascarella, Marco A, Olonisakin, Tolani F, Rumde, Purva, Vendra, Varun, Nance, Melonie A, Kim, Seungwon, Kubik, Mark W, Sridharan, Shaum S, Ferris, Robert L, Fenton, Moon J, Clayburgh, Daniel R, Ohr, James P, Joyce, Sonali C, Sen, Malabika, Herman, James G, Grandis, Jennifer R, Zandberg, Dan P, Duvvuri, Umamaheswar

“…Neoadjuvant targeted therapy provides a brief, preoperative window of opportunity that can be exploited to individualize cancer care based on treatment…”
Get full text

Abstract 3853: The TWIST1-p27 signaling pathway is a critical determinant of MET TKI cell cycle arrest and resistance in MET altered non-small cell lung cancer by Kumar, Vinod, Yochum, Zachary A., Devadassan, Princey, Huang, Eric, Miller, Ethan, Ayyala, Vasavi, Rumde, Purva H., Baruwal, Roja, O’Brien, James, Stabile, Laura P., Burns, Timothy F.

“…Advancement in classifying NSCLC into molecularly defined subgroup that respond to specific therapies have shifted the treatment paradigm towards personalized…”
Get full text

Abstract 4743: Targeting a novel TWIST1-Hexokinase II pathway to overcome MET TKI resistance in NSCLC by Rumde, Purva H., Cargill, Kasey R., Kumar, Vinod, Devadassan, Princey, Chen, Jason, McGraw-Sapp, Leviticus, Wu, Xiaxuan, Dacic, Sanja, Bao, Riyue, Sivakama, Bharathri, Goetzman, Eric S., Agnihotri, Sameer, Mullett, Steven J., Wendell, Stacey G., Stabile, Laura P., Burns, Timothy F.

“…Non-small cell lung cancer (NSCLC) is the most common primary tumor to metastasize to the brain, with up to 40% of NSCLC patients developing brain metastases…”
Get full text

Abstract 1091: TWIST1 inhibition overcomes resistance to tyrosine kinase inhibitors in MET driven non-small cell lung cancer by Kumar, Vinod, Yochum, Zachary A., Devadassan, Princey, Huang, Eric, Miller, Ethan, Ayyala, Vasavi, Stabile, Laura P., Burns, Timothy F., Rumde, Purva H.

“…Background: The mesenchymal-epidermal transition (cMET/MET) tyrosine kinase receptor and its ligand, the hepatocyte growth factor (HGF) are overexpressed in a…”
Get full text

Abstract 4338: Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit by Mascarella, Marco Antonio, Olonisakin, Tolani, Rumde, Purva, Vendra, Varun, Nance, Melonie, Kim, Seungwon, Kubik, Mark, Sridharan, Shaum, Ferris, Robert, Fenton, Moon, Clayburgh, Daniel, Ohr, James, Sen, Malabika, Joyce, Sonali, Herman, James, Grandis, Jennifer, Zandberg, Dan, Duvvuri, Umamaheswar

“…Purpose: Neoadjuvant targeted therapy provides a brief, preoperative ‘window of opportunity’ that can be exploited to individualize cancer care based on…”
Get full text